{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T20:27:25Z","timestamp":1778012845846,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1016\/j.ejca.2009.02.020","type":"journal-article","created":{"date-parts":[[2009,3,30]],"date-time":"2009-03-30T20:08:36Z","timestamp":1238443716000},"page":"1111-1116","source":"Crossref","is-referenced-by-count":10,"title":["TNM: Therapeutically Not Mandatory"],"prefix":"10.1016","volume":"45","author":[{"given":"Richard J.","family":"Epstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2009.02.020_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.breast.2005.11.011","article-title":"Rethinking TNM: breast cancer TNM classification for treatment decision-making and research","volume":"15","author":"Veronesi","year":"2006","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.ejca.2009.02.020_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/ssu.10014","article-title":"TNM: evolution and relation to other prognostic factors","volume":"21","author":"Sobin","year":"2003","journal-title":"Semin Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2009.02.020_bib3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/ssu.10020","article-title":"New TNM melanoma staging system: linking biology and natural history to clinical outcomes","volume":"21","author":"Balch","year":"2003","journal-title":"Semin Surg Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2009.02.020_bib4","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.breast.2007.05.006","article-title":"T4 breast cancer under closer inspection: a case for revision of the TNM classification","volume":"16","author":"Guth","year":"2007","journal-title":"Breast"},{"issue":"7","key":"10.1016\/j.ejca.2009.02.020_bib5","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S1470-2045(07)70205-X","article-title":"The future of the TNM staging system in colorectal cancer: time for a debate?","volume":"8","author":"Quirke","year":"2007","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2009.02.020_bib6","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00262-007-0445-6","article-title":"Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: an update","volume":"57","author":"Beachy","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ejca.2009.02.020_bib7","doi-asserted-by":"crossref","first-page":"5928","DOI":"10.2741\/3127","article-title":"Cytogenetic biomarkers for human cancer","volume":"13","author":"Keen-Kim","year":"2008","journal-title":"Front Biosci"},{"issue":"5","key":"10.1016\/j.ejca.2009.02.020_bib8","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1634\/theoncologist.2007-0248","article-title":"Commercialized multigene predictors of clinical outcome for breast cancer","volume":"13","author":"Ross","year":"2008","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.ejca.2009.02.020_bib9","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1373\/clinchem.2008.110056","article-title":"A personalized approach to cancer treatment: how biomarkers can help","volume":"54","author":"Duffy","year":"2008","journal-title":"Clin Chem"},{"issue":"24","key":"10.1016\/j.ejca.2009.02.020_bib10","doi-asserted-by":"crossref","first-page":"8019","DOI":"10.1158\/1078-0432.CCR-08-0974","article-title":"Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer","volume":"14","author":"Dowsett","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.ejca.2009.02.020_bib11","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1002\/1097-0142(20010401)91:7<1231::AID-CNCR1123>3.0.CO;2-K","article-title":"The impact of a multidisciplinary breast cancer center on recommendations for patient management: the University of Pennsylvania experience","volume":"91","author":"Chang","year":"2001","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2009.02.020_bib12","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1002\/cncr.22266","article-title":"Changes in surgical management resulting from case review at a breast cancer multidisciplinary tumor board","volume":"107","author":"Newman","year":"2006","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2009.02.020_bib13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1373\/clinchem.2005.056952","article-title":"Conflict between guideline methodologic quality and recommendation validity: a potential problem for practitioners","volume":"52","author":"Watine","year":"2006","journal-title":"Clin Chem"},{"issue":"7","key":"10.1016\/j.ejca.2009.02.020_bib14","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1172\/JCI31399","article-title":"Improved prediction of prostate cancer recurrence through systems pathology","volume":"117","author":"Cordon-Cardo","year":"2007","journal-title":"J Clin Invest"},{"issue":"2 Suppl.","key":"10.1016\/j.ejca.2009.02.020_bib15","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1016\/j.ijrobp.2007.05.044","article-title":"Swing of the surgical pendulum: a return to surgery for treatment of head and neck cancer in the 21st century?","volume":"69","author":"Holsinger","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"10.1016\/j.ejca.2009.02.020_bib16","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.4065\/82.9.1131","article-title":"A multidisciplinary approach to the management of breast cancer, part 2: therapeutic considerations","volume":"82","author":"Pruthi","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ejca.2009.02.020_bib17","series-title":"Adjuvant therapy of cancer","first-page":"455","article-title":"Time without symptoms and toxicity (TWiST): a quality-of-life-oriented endpoint to evaluate adjuvant therapy","author":"Gelber","year":"1987"},{"issue":"12","key":"10.1016\/j.ejca.2009.02.020_bib18","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1007\/s00259-003-1264-4","article-title":"Sentinel lymph nodes in gynaecological malignancies: frontline between TNM and clinical staging systems?","volume":"30","author":"Zambo","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1016\/j.ejca.2009.02.020_bib19","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/j.1365-2036.2008.03684.x","article-title":"Review article: current management of metastatic colorectal cancer \u2013 the evolving impact of targeted drug therapies","volume":"27","author":"Yau","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ejca.2009.02.020_bib20","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0140-6736(80)91066-1","article-title":"Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer","volume":"i","author":"Powles","year":"1980","journal-title":"Lancet"},{"issue":"9278","key":"10.1016\/j.ejca.2009.02.020_bib21","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0140-6736(01)05483-6","article-title":"Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis","volume":"358","author":"Cole","year":"2001","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ejca.2009.02.020_bib22","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1038\/sj.bjc.6601366","article-title":"Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer","volume":"89","author":"Cameron","year":"2003","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2009.02.020_bib23","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/nrc1473","article-title":"The CXCL12-CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies","volume":"4","author":"Epstein","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2009.02.020_bib24","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(62)91475-7","article-title":"Cancer: an attack on cytologism","volume":"i","author":"Smithers","year":"1962","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2009.02.020_bib25","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/1097-0142(19800815)46:4+<1009::AID-CNCR2820461326>3.0.CO;2-H","article-title":"The contribution of NSABP trials of primary breast cancer therapy to an understanding of tumor biology: an overview of findings","volume":"46","author":"Fisher","year":"1980","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2009.02.020_bib26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000226443","article-title":"Complete remission following endocrine or combined cytotoxic and hormonal treatment in advanced breast cancer","volume":"44","author":"Pedrazzini","year":"1987","journal-title":"Oncology"},{"issue":"11","key":"10.1016\/j.ejca.2009.02.020_bib27","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"issue":"1 Suppl.","key":"10.1016\/j.ejca.2009.02.020_bib28","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/cncr.2820741327","article-title":"Adjuvant systemic therapy for early breast cancer","volume":"74","author":"Henderson","year":"1994","journal-title":"Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980490900149X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980490900149X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T14:12:09Z","timestamp":1564755129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980490900149X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["S095980490900149X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2009.02.020","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}